Hyderabad, June 13 -- Bharat Biotech International Limited (BBIL), a leading vaccine manufacturer based in Hyderabad, has announced a major partnership with global pharmaceutical giant GSK plc to advance the development of altSonflex1-2-3, an innovative vaccine candidate targeting Shigellosis-a severe form of bacterial diarrhoea that poses a significant threat to children under five, especially in low- and middle-income countries.

Under the agreement, Bharat Biotech has in-licensed the vaccine candidate from GSK, which has already completed Phase I and II clinical trials in Europe and Africa.

These early-stage trials demonstrated a favourable safety profile and strong immune response, with no safety concerns reported in African infants ...